RAD51 and cancer: Additionally, using a structure-led fragment-based approach, CAM833 was recently identified as a small molecule that prevented RAD51-BRCA2 interactions and hence nucleofilament formation, and synergised with IR and PARP inhibitors in cancer cells [187].